Natera (NTRA) Stock Forecast & Price Target

Natera is positioned favorably because Signatera sits in a more than $15B MRD market where it has over 90% share, supported by durable reimbursement advantages that create a meaningful moat versus new entrants. Growth is further reinforced by ~60% clinical volume growth in 2025, expanding Medicare coverage, and a rising ASP of $1,275 that remains well below the $3,590 Medicare rate, leaving room for revenue and margin expansion as COGS per test has fallen more than $100 since 2022. Beyond core oncology, pharma engagement around clinical trials and data licensing could add another underappreciated growth leg, with management seeing credible eight-to-nine-figure deals and approximately $70M of revenue in 2026, while the company also targets 25%+ EBIT margins over time.

Natera is facing a negative fundamental setup because its growth narrative depends on assumptions that may already be stretched: MRD adoption in mature uses like CRC adjuvant reportedly exceeds 50%, limiting incremental upside, while the broader competitive landscape is increasingly crowded and could pressure share in both oncology and women’s health. Although MRD ASPs have risen from roughly $500 to $1,250 over the past five years, the path to $2,000 may not be linear, and management itself warned that faster adoption of Ultra Signatera could outpace COGS declines and temporarily hurt gross margins. Even the bullish catalysts look delayed and uncertain, with colorectal screening results expected in mid-2027, commercial launch targeted for 2028–2029, and prior catalysts such as guideline updates and trials showing inconsistent realization.